Trial · NCT01325181
Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
NCT01325181, Phase 1, Phase 2, Completed, Jang Won Heo; results first posted 2013-05-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy. Trials, record NCT01325181. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01325181
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
- NCT number
- NCT01325181
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Jang Won Heo
- Conditions
- Chronic Central Serous Chorioretinopathy
- Interventions
- Verteporfin, ranibizumab
- First posted
- 2011-03-29
- Last updated
- 2013-05-27
- Results first posted
- 2013-05-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment | 12 months | number of participants who achieved complete resolution of subretinal fluid on OCT without rescue treatment until the end of the study |
| Secondary | Change From Baseline in logMAR BCVA | 12 months | the changes from baseline in logMAR BCVA throughout the follow-up period |
| Secondary | Change From Baseline in Central Foveal Thickness on OCT | 12 months | the change from baseline in central foveal thickness measured by OCT throughout the follow-up period |
| Secondary | Number of Participants With Leakage on Fluorescein Angiography | 12 months | number of participants who showed fluorescein leakage after primary or rescue treatment throughout the follow-up period |
| Secondary | Change From Baseline in Choroidal Hyperpermeability on Indocyanine Green Angiography | 12 months | change from baseline in the status of choroidal perfusion and hyperpermeability on indocyanine green angiography throughout the follow-up period |
| Secondary | Number of Participants Who Underwent Rescue Treatment | 12 months | number of participants who underwent rescue treatment: ranibizumab injections for the low-fluence PDT group and low-fluence PDT for the ranibizumab group |
| Secondary | Number of Participants With Adverse Event | 12 months | number of participants with adverse event throughout the follow-up period including procedure and drug-related adverse events |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change From Baseline in logMAR BCVA | 12 months | |||
| PRIMARY | Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment | 12 months | All study eyes were analyzed using intention to treat principle and the last observation forward method | participants | NUMBER |
| SECONDARY | Change From Baseline in Central Foveal Thickness on OCT | 12 months | |||
| SECONDARY | Number of Participants With Leakage on Fluorescein Angiography | 12 months | |||
| SECONDARY | Change From Baseline in Choroidal Hyperpermeability on Indocyanine Green Angiography | 12 months | |||
| SECONDARY | Number of Participants Who Underwent Rescue Treatment | 12 months | |||
| SECONDARY | Number of Participants With Adverse Event | 12 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment | Low-fluence PDT | 16 | participants | ||
| Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment | Ranibizumab | 2 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Low-fluence PDT | 18 | |
| Overall Study | STARTED | Ranibizumab | 16 | |
| Overall Study | COMPLETED | Low-fluence PDT | 18 | |
| Overall Study | COMPLETED | Ranibizumab | 14 | |
| Overall Study | NOT COMPLETED | Low-fluence PDT | 0 | |
| Overall Study | NOT COMPLETED | Ranibizumab | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Low-fluence PDT | ||
| Total, all-cause mortality | Ranibizumab | ||
| Total, other adverse events | Low-fluence PDT | 0 | 0 |
| Total, other adverse events | Ranibizumab | 0 | 0 |
| Total, serious adverse events | Low-fluence PDT | 0 | 0 |
| Total, serious adverse events | Ranibizumab | 0 | 0 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Low-fluence PDT vs Ranibizumab: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01325181
GET https://conductscience.org/api/trials/v1/NCT01325181/registered